Feature | April 08, 2013

Transesophageal Echocardiograms on Patients With Known Clots May Be Overused

The American Society of Echocardiography releases list of “Five Things Physicians and Patients Should Question”

Transesophageal Echocardiogram

April 8, 2013 — The American Society of Echocardiography (ASE) has released a list of five interventions whose appropriateness physicians and patients should discuss as part of Choosing Wisely, an initiative of the ABIM Foundation, along with Consumer Reports. Fifth on the list, they ask that patients and their doctors talk about the real need for a transesophageal echocardiography (TEE) if the patient’s clot treatment is not likely to be modified.

Avoid TEE to detect cardiac sources of embolization, if a source has been identified and patient management will not change.

TEE involves taking echo pictures from within the body to allow the imaging device to be placed directly next to the heart, so the quality of the images is enhanced and allows for identification of possible sources of a stroke including blood clots within the heart. Placing the imaging probe into the mouth and then advancing it into the esophagus of the patient on whom it is performed, is not without risk. In order to do this safely and comfortably, sedatives are administered and a local anesthetic is gargled in the mouth. Both the administration of these medications and placing of the probe in the esophagus are not entirely benign procedures, and, while complications rarely occur, there is a possibility of damage to the esophagus and choking or aspiration. Because of these risk factors, the procedure should only be done when the care of the patient will possibly change based upon the result.

When clots are thought to be the cause of a stroke and their source has been identified, blood thinners are usually started to prevent a second stroke. In some cases, doctors make the decision to use blood thinners such as warfarin or Coumadin even when there is no definite clot found. In other cases, these blood thinners are contraindicated due to a problem with bleeding. In both of these scenarios, further information about the cardiac source would not change the treatment thus even the small risk of the TEE is not justified.

For more information: www.choosingwisely.org, www.asecho.org


Related Content

News | Transesophageal Echo (TEE)

January 31, 2024 — Royal Philips, a global leader in health technology, announced that its latest TEE transducer ...

Home January 31, 2024
Home
News | Transesophageal Echo (TEE)

June 30, 2022 — Clarius Mobile Health, a leading provider of high-definition wireless ultrasound systems, and ImaCor Inc ...

Home June 30, 2022
Home
News | Transesophageal Echo (TEE)

June 7, 2022 — Visura Technologies, Inc., a privately-held medical device company dedicated to delivering state-of-the ...

Home June 07, 2022
Home
News | Transesophageal Echo (TEE)

February 5, 2019 – The American Society of Echocardiography (ASE) released a new document that provides a comprehensive ...

Home February 05, 2019
Home
Sponsored Content | Case Study | Transesophageal Echo (TEE) | Cyril Danielkutty B.E., Dillon Weiss, B.S., Chad A Kliger, M.D., M.S.

Transcatheter interventions have become a mainstay in cardiac care as treatments for structural and congenital heart ...

Home September 05, 2018
Home
Technology | Transesophageal Echo (TEE)

July 10, 2018 — Evanston, Ill.-based startup Visura Technologies has received 510(k) clearance from the U.S. Food and ...

Home July 10, 2018
Home
Technology | Transesophageal Echo (TEE)

June 20, 2017 — Dutch medical device company Stroke2prevent BV recently announced it has received U.S. Food and Drug ...

Home June 20, 2017
Home
News | Transesophageal Echo (TEE)

April 21, 2016 — CS Medical announced the release of their newest product designed to aid in the circle of care for ...

Home April 21, 2016
Home
Subscribe Now